Robert M Dean MD

Hematologic Oncology

Staff, Cleveland Clinic Taussig Cancer Institute | Assistant Professor, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University

Join to view full profile

9500 Euclid AveCleveland, OH 44195
Phone+1 800-223-2273

Dr. Dean is on Doximity

As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Dean's full profile Already have an account?

Summary

Dr. Robert Dean is an oncologist based in Cleveland, OH, specializing in hematologic oncology. He obtained his medical degree from the Perelman School of Medicine at the University of Pennsylvania and completed his residency training in Internal Medicine at Boston University Medical Center and fellowship in Hematology and Medical Oncology at the National Cancer Institute, based at the National Institutes of Health Clinical Center. Dr. Dean has served as a Staff Physician at the Cleveland Clinic since 2005, where he is also an Assistant Professor of Medicine and Medical Director for the Epic Beacon Module in the Information Technology Division. His clinical expertise includes lymphomas, bone marrow transplantation, and cellular immunotherapy. He has contributed to publications in reputable journals such as the Journal of Clinical Oncology and Blood Advances, and has been recognized for his work with a CMS Meaningful Use Stage 1 Certification from Epic Systems Corporation.

Education & Training

National Institutes of Health Clinical CenterFellowship, Hematology and Medical Oncology, 2000 - 2005
Boston University Medical CenterFellowship, Hematology and Medical Oncology, 1999 - 2000
Boston University Medical CenterResidency, Internal Medicine, 1996 - 1999
Perelman School of Medicine at the University of PennsylvaniaClass of 1996

The following disclaimer is related to board certifications obtained from ABMS®, denoted by the ABMS® logo.

This information is proprietary data maintained in a copyrighted database owned by the American Board of Medical Specialties®. The display and presence of ABMS Data in no way constitutes any affiliation, association with, or endorsement of any advertising, promotion, or sponsorship by ABMS and its affiliates and subsidiaries, the ABMS Member Boards, or ABMS board certified physicians and medical specialists. Copyright 2026 American Board of Medical Specialties®. All rights reserved.

The user is responsible for ensuring that the profile obtained in this directory is the profile of the physician or medical specialist being sought.

A self-designated specialty, subspecialty, or practice area neither implies nor is equivalent to ABMS board certification or the existence of specialized training by or competence of a physician or medical specialist.

Certifications & Licensure

OH State Medical License 2005 - 2027
MA State Medical License 1998 - 2005
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 2 Certification Beacon Oncology 2014 Certified Module, Epic Systems Corporation, 2011, 2013-2017
CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory - Core EMR, Epic Systems Corporation, 2011, 2013-2017
CMS Meaningful Use Stage 2 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2011, 2013-2017

Publications & Presentations

PubMed

1 citations
Neighborhood Socioeconomic Disadvantage and Distance From Treatment Center do not Impact Survival Outcomes of Patients With Non-Hodgkin Lymphoma and Multiple Myeloma T...
Agrima Mian, Rafaella Litvin, Danai Dima, Betty K Hamilton, Allison Winter
Transplantation and Cellular Therapy. 2026-10-01
1 citations
Carfilzomib in combination with R-CHOP for initial treatment of patients with non-germinal center diffuse large B-cell lymphoma: a multicenter, single arm, phase 1/2 s...
Brian T Hill, Pallawi Torka, Francisco Hernandez-Ilizaliturri, Robert Dean, Deepa Jagadeesh
Leukemia & Lymphoma. 2025-09-01
Lenalidomide, rituximab (R), and ixazomib for frontline treatment of high risk follicular and indolent non-Hodgkin lymphoma.
Brian T Hill, Yanwen Chen, Deepa Jagadeesh, Robert Dean, Omer Koc
Leukemia & Lymphoma. 2024-06-01

Journal Articles

Effect of Bone Marrow CD34+Cells and T-cell Subsets on Clinical Outcomes After Myeloablative Allogeneic Hematopoietic Cell Transplantation
Deepa Jagadeesh, Matt Kalaycio, Brian Bolwell, Betty K Hamilton, Brian Hill, Brad Pohlman, Robert Dean, Navneet S Majhail, Sagar S Patel, Rabi Hanna, Aaron T Gerds, Ro..., Nature
Neutropenic Fever During Peripheral Blood Progenitor Cell Mobilization Is Associated with Decreased CD34+ Cell Collection and Increased Apheresis Collection Days
Mat Kalaycio, Robert Dean, Jack Khouri, Brad Pohlman, Aleksandr Lazaryan, Edward Copelan, Steven Andresen, Ronald Sobecks, Hien Liu, Journal of Clinical Apheresis

Abstracts/Posters

Depth of Pre-Treatment Immunoparesis Is an Important Prognostic Factor for Survival in Relapsed Multiple Myeloma
Robert M. Dean, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Outcomes and Factors Impacting Use of Axicabtagene Ciloleucel in Refractory and Relapsed Large B-Cell Lymphoma: An Intent-to-Treat Analysis
Robert M. Dean, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Targeted Treatment and Survival Following Relapse after Allogeneic Hematopoietic Cell Transplantation for Acute Leukemia and MDS in the Contemporary Era
Robert M. Dean, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019

Lectures

Phase I Trial of Carfilzomib + R-CHOP (CarR-CHOP) for Frontline Treatment of Patients with Diffuse Large B-Cell Lymphoma (DLBCL)
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Impact of Clinical Versus Biochemical Progression on Post-Progression Survival in Multiple Myeloma
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Association of MHC Class I Chain-Related Gene a (MICA) Polymorphisms with Allogeneic Hematopoietic Cell Transplantation Outcomes in Acute Myeloid Leukemia
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018